A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Study Summary

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Conditions

Myeloproliferative Neoplasms

Interventions / Drugs

INCB160058 Standard disease-directed therapy

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment186 participants

Primary Completion—

Lead SponsorIncyte Corporation

Data Retrieved2026-04-11 02:55:29.647754+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.